TWI704920B - 用於減輕ｃｄ３特異性結合域所導致可能不良事件之抗-白血球黏附 - Google Patents

用於減輕ｃｄ３特異性結合域所導致可能不良事件之抗-白血球黏附 Download PDF

Info

Publication number
TWI704920B
TWI704920B TW103104162A TW103104162A TWI704920B TW I704920 B TWI704920 B TW I704920B TW 103104162 A TW103104162 A TW 103104162A TW 103104162 A TW103104162 A TW 103104162A TW I704920 B TWI704920 B TW I704920B
Authority
TW
Taiwan
Prior art keywords
cells
cell
endothelial
adhesion molecules
amg
Prior art date
Application number
TW103104162A
Other languages
English (en)
Chinese (zh)
Other versions
TW201442714A (zh
Inventor
吉爾哈德 魯格梅爾
狄爾克 那高爾森
朱爾根 史其爾
彼得 庫佛
馬休斯 凱林格爾
派翠克 霍夫曼
維爾吉尼 娜格爾
伊蓮 派蘇帕堤 多普菲
Original Assignee
德商安美基研究（慕尼黑）公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德商安美基研究（慕尼黑）公司 filed Critical 德商安美基研究（慕尼黑）公司
Publication of TW201442714A publication Critical patent/TW201442714A/zh
Application granted granted Critical
Publication of TWI704920B publication Critical patent/TWI704920B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
TW103104162A 2013-02-08 2014-02-07 用於減輕ｃｄ３特異性結合域所導致可能不良事件之抗-白血球黏附 TWI704920B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361762718P 2013-02-08 2013-02-08
US61/762,718 2013-02-08
US201361811526P 2013-04-12 2013-04-12
US61/811,526 2013-04-12

Publications (2)

Publication Number Publication Date
TW201442714A TW201442714A (zh) 2014-11-16
TWI704920B true TWI704920B (zh) 2020-09-21

Family

ID=50231117

Family Applications (2)

Application Number Title Priority Date Filing Date
TW103104162A TWI704920B (zh) 2013-02-08 2014-02-07 用於減輕ｃｄ３特異性結合域所導致可能不良事件之抗-白血球黏附
TW107140068A TW201929865A (zh) 2013-02-08 2014-02-07 用於減輕cd3特異性結合域所導致可能不良事件之抗-白血球黏附

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW107140068A TW201929865A (zh) 2013-02-08 2014-02-07 用於減輕cd3特異性結合域所導致可能不良事件之抗-白血球黏附

Country Status (12)

Country Link
US (2) US9688760B2 (enExample)
EP (2) EP2953630B1 (enExample)
JP (2) JP6567425B2 (enExample)
AR (1) AR094740A1 (enExample)
AU (2) AU2014214020B2 (enExample)
CA (1) CA2898032C (enExample)
ES (1) ES2811764T3 (enExample)
JO (1) JO3529B1 (enExample)
MX (2) MX368842B (enExample)
TW (2) TWI704920B (enExample)
UY (1) UY35313A (enExample)
WO (1) WO2014122251A2 (enExample)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2701741B1 (en) * 2011-04-28 2020-06-10 Amgen Research (Munich) GmbH Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects
EP2747781B1 (en) 2011-08-23 2017-11-15 Roche Glycart AG Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
WO2014056783A1 (en) 2012-10-08 2014-04-17 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
JO3529B1 (ar) * 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
US9486475B2 (en) * 2013-02-08 2016-11-08 Amgen Research (Munich) Gmbh PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
JP6499087B2 (ja) 2013-02-26 2019-04-10 ロシュ グリクアート アーゲー 二重特異性ｔ細胞活性化抗原結合分子
WO2014131712A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
US10101247B2 (en) * 2013-07-19 2018-10-16 Rarecyte, Inc. Solution and method for adhering suspension components to a substrate
MX379030B (es) 2013-12-17 2025-03-10 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
FI3531133T3 (fi) 2014-05-30 2023-11-02 Amgen Res Munich Gmbh Prekursori-b-solujen akuutin lymfoblastisen leukemian potilaiden riskiluokittelu
RS65573B1 (sr) 2014-08-04 2024-06-28 Hoffmann La Roche Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije
MA40579A (fr) 2014-09-12 2016-03-17 Genentech Inc Anticorps anti-cll-1 et immunoconjugués
BR112017010513A2 (pt) 2014-11-20 2018-04-03 F. Hoffmann-La Roche Ag ?cadeias leves comuns e métodos de uso?
FI4141032T3 (fi) 2014-11-20 2024-07-31 Hoffmann La Roche T-solua aktivoivien bispesifisten antigeeniä sitovien molekyylien ja pd-1-akselia sitovien antagonistien yhdistelmähoito
EP3221356B1 (en) 2014-11-20 2020-09-02 F.Hoffmann-La Roche Ag T cell activating bispecific antigen binding molecules against folr1 and cd3
HRP20231134T1 (hr) 2015-06-16 2024-01-05 F. Hoffmann - La Roche Ag Humanizirana i afinitetno zrela protutijela na fcrh5 i postupci za uporabu
CN107847568B (zh) 2015-06-16 2022-12-20 豪夫迈·罗氏有限公司 抗cll-1抗体和使用方法
WO2017040324A1 (en) * 2015-08-28 2017-03-09 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
CN106554414B (zh) * 2015-09-18 2019-04-23 上海科济制药有限公司 抗cd19全人抗体以及靶向cd19的免疫效应细胞
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
KR20180073561A (ko) 2015-10-02 2018-07-02 에프. 호프만-라 로슈 아게 이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자
US10101248B1 (en) * 2015-12-02 2018-10-16 Rarecyte, Inc. Solution and method for adhering suspension components to a substrate
AU2016368469B2 (en) 2015-12-09 2023-11-02 F. Hoffmann-La Roche Ag Type II anti-CD20 antibody for reducing formation of anti-drug antibodies
AR107303A1 (es) 2016-01-08 2018-04-18 Hoffmann La Roche Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
LT3433280T (lt) 2016-03-22 2023-07-10 F. Hoffmann-La Roche Ag Proteazės aktyvuojamos t ląstelei bispecifinės molekulės
US12144850B2 (en) 2016-04-08 2024-11-19 Purdue Research Foundation Methods and compositions for car T cell therapy
JP6225321B1 (ja) * 2016-08-31 2017-11-08 王子ホールディングス株式会社 ポリ硫酸ペントサンの製造方法
EP3677587A4 (en) 2016-08-31 2021-04-14 Oji Holdings Corporation XYLOOLIGOSACCHARIDE ACID, AND METHOD FOR MANUFACTURING THE SAME
US10882918B2 (en) 2016-09-30 2021-01-05 Hoffmann-La Roche Inc. Bispecific T cell activating antigen binding molecules
KR20190074300A (ko) 2016-11-15 2019-06-27 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
AU2018219226B2 (en) 2017-02-07 2024-12-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
JP6281659B1 (ja) 2017-02-28 2018-02-21 王子ホールディングス株式会社 ポリ硫酸ペントサン、医薬組成物及び抗凝固剤
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
US11344578B2 (en) 2017-04-19 2022-05-31 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
CA3065747C (en) 2017-05-31 2024-10-01 Oji Holdings Corporation MOISTURIZING COMPOSITION CONTAINING PENTOSANNE POLYSULFATE
AU2018333249B2 (en) 2017-09-12 2023-03-02 Oji Holdings Corporation Pentosan polysulfate and method for producing pentosan polysulfate
CN111148533A (zh) 2017-09-19 2020-05-12 麻省理工学院 用于嵌合抗原受体t细胞疗法的组合物及其用途
WO2019124363A1 (ja) 2017-12-20 2019-06-27 王子ホールディングス株式会社 ポリ硫酸ペントサン及びポリ硫酸ペントサンを含む医薬
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
WO2019156795A1 (en) 2018-02-06 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
AR115360A1 (es) 2018-02-08 2021-01-13 Genentech Inc Moléculas de unión al antígeno y métodos de uso
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
CA3091674A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
AU2019346335B2 (en) 2018-09-28 2024-07-25 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
EP3962948A1 (en) * 2019-04-30 2022-03-09 Amgen Research (Munich) GmbH Means and methods of treating burkitt lymphoma or leukemia
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
US11642409B2 (en) 2019-06-26 2023-05-09 Massachusetts Insttute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
BR112022011357A2 (pt) 2019-12-13 2022-08-23 Genentech Inc Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo
KR20220163940A (ko) 2020-02-04 2022-12-12 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 항-디니트로페놀 키메라 항원 수용체
US11896619B2 (en) 2020-03-10 2024-02-13 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of NPM1c-positive cancer
CA3173527A1 (en) 2020-03-10 2021-09-16 Massachusetts Institute Of Technology Methods for generating engineered memory-like nk cells and compositions thereof
CA3171235A1 (en) * 2020-03-12 2021-09-16 Sydney David Cullis-Hill Treatment for coronavirus infection and associated cytokine toxicity
WO2021221782A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
WO2021221783A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
TWI852680B (zh) 2020-06-19 2024-08-11 瑞士商赫孚孟拉羅股份公司 與 cd3 及 cd19 結合之抗體
WO2022060901A1 (en) * 2020-09-16 2022-03-24 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
TWI874719B (zh) 2020-11-04 2025-03-01 美商建南德克公司 用抗cd20/抗cd3雙特異性抗體進行治療之給藥
AU2021374590A1 (en) 2020-11-04 2023-06-01 Genentech, Inc. Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
KR20230095113A (ko) 2020-11-04 2023-06-28 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체들과 항-cd79b 항체 약물 접합체들을 이용한 치료를 위한 투약
CN112521513B (zh) * 2020-12-15 2021-08-24 青岛西凯生物技术有限公司 一种靶向cd19的嵌合抗原受体(car)及其应用
WO2022228705A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
KR20240007171A (ko) 2021-05-14 2024-01-16 제넨테크, 인크. 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법
WO2022251253A1 (en) 2021-05-24 2022-12-01 Provention Bio, Inc. Methods for treating type 1 diabetes
CN113637087A (zh) * 2021-07-09 2021-11-12 上海易慕峰生物科技有限公司 一种提高细胞免疫疗法安全性的嵌合受体和细胞
US20260083848A1 (en) 2021-11-03 2026-03-26 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2024206166A1 (en) * 2023-03-31 2024-10-03 Memorial Sloan-Kettering Cancer Center Microenvironment actuated t-cells and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010037836A2 (en) * 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific psmaxcd3 bispecific single chain antibody
WO2012062596A1 (en) * 2010-11-10 2012-05-18 Micromet Gmbh Prevention of adverse effects caused by cd3 specific binding domains

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2689848A (en) 1951-02-06 1954-09-21 Wander Ag Dr A Salts of sulfuric acid esters of xylan
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
AU687755B2 (en) * 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
KR100508289B1 (ko) 1998-04-21 2005-08-17 마이크로메트 에이지 Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
SI1976886T1 (sl) 2005-12-16 2015-03-31 Amgen Research (Munich) Gmbh Sredstva in postopki za zdravljenje tumorskih bolezni
AU2007248019B2 (en) 2006-05-03 2012-10-11 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Chimeric T cell receptors and related materials and methods of use
MX2008015771A (es) * 2006-06-14 2009-01-27 Macrogenics Inc Metodos para el tratamiento de padecimientos autoinmunes usando anticuerpos monoclonales con toxicidad reducida.
WO2008107906A1 (en) 2007-03-06 2008-09-12 Alembic Limited Process for the preparation of pentosan polysulfate or salts thereof
SG10201808730VA (en) * 2007-04-03 2018-11-29 Amgen Res Munich Gmbh Cross-species-specific binding domain
CN109456410B (zh) 2007-04-03 2022-01-28 安进研发（慕尼黑）股份有限公司 跨物种特异性CD3-ε结合结构域
US20100183615A1 (en) 2007-04-03 2010-07-22 Micromet Ag Cross-species-specific bispecific binders
EA201000219A1 (ru) * 2007-07-17 2010-12-30 Комбинейторкс, Инкорпорейтед Способ и композиция для лечения в-клеточных пролиферативных нарушений
WO2009011897A1 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Combinations for the treatment of b-cell proliferative disorders
EP2188281A1 (en) 2007-08-10 2010-05-26 Y's Therapeutics Co, Ltd. Modulation of immune responses by administration of roxithromycin or its derivative
US8026343B2 (en) * 2008-08-08 2011-09-27 Dinona Inc. Antibody modulating the differentiation and function of dendritic cells via binding intercellular adhesion molecule-1 and use thereof
BR112012009778A2 (pt) * 2009-10-27 2017-06-13 Micromet Ag regime de dosagem para administrar um anticorpo biespecífico de cd19xcd3
KR101889995B1 (ko) * 2010-10-27 2018-08-20 암젠 리서치 (뮌헨) 게엠베하 Dlbcl의 치료 수단 및 방법
US9402865B2 (en) * 2011-01-18 2016-08-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
EP2701741B1 (en) * 2011-04-28 2020-06-10 Amgen Research (Munich) GmbH Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CN102875685B (zh) 2012-09-29 2013-12-25 郑骏年 嵌合抗原受体hFⅦL-CD8-OX40-CD3ζ及其用途
US9486475B2 (en) * 2013-02-08 2016-11-08 Amgen Research (Munich) Gmbh PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
JO3529B1 (ar) * 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010037836A2 (en) * 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific psmaxcd3 bispecific single chain antibody
WO2012062596A1 (en) * 2010-11-10 2012-05-18 Micromet Gmbh Prevention of adverse effects caused by cd3 specific binding domains

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M. Hopfner et al.;"Selectin-blocking semisynthetic sulfated polysaccharides as promising anti-inflammatory agents";Journal of Pharmacy and Pharmacology,2003,55:697-706. *

Also Published As

Publication number Publication date
CA2898032C (en) 2021-06-15
JP6567425B2 (ja) 2019-08-28
US20140227272A1 (en) 2014-08-14
MX368842B (es) 2019-10-18
MX2019012421A (es) 2022-10-13
JP2016514090A (ja) 2016-05-19
ES2811764T3 (es) 2021-03-15
UY35313A (es) 2014-08-29
WO2014122251A3 (en) 2014-10-02
CA2898032A1 (en) 2014-08-14
EP2953630B1 (en) 2020-07-01
TW201929865A (zh) 2019-08-01
AU2014214020B2 (en) 2018-11-15
WO2014122251A2 (en) 2014-08-14
AU2019200841B2 (en) 2020-08-13
EP2953630A2 (en) 2015-12-16
AU2014214020A1 (en) 2015-07-30
HK1216996A1 (zh) 2016-12-16
US9688760B2 (en) 2017-06-27
JP6933684B2 (ja) 2021-09-08
MX2015009922A (es) 2015-09-25
TW201442714A (zh) 2014-11-16
JP2019178142A (ja) 2019-10-17
EP3760210A1 (en) 2021-01-06
AU2019200841A1 (en) 2019-02-28
US20170327581A1 (en) 2017-11-16
AR094740A1 (es) 2015-08-26
US11084876B2 (en) 2021-08-10
JO3529B1 (ar) 2020-07-05

Similar Documents

Publication Publication Date Title
JP6933684B2 (ja) Ｃｄ３特異的結合ドメインによって引き起こされる潜在的有害事象を緩和するための抗白血球接着
US11579142B2 (en) Dosage regimen for administering a CD19xCD3 bispecific antibody to patients at risk for potential adverse effects
US10662243B2 (en) Dosage regimen for administering a CD19XCD3 bispecific antibody
AU2018200915A1 (en) Prevention of Adverse Effects Caused by CD3 Specific Binding Domains
JP2016534090A (ja) Ｃｄ３８アゴニストの医学的使用
JP2020502147A (ja) 制御性ｂ１０細胞を枯渇させる抗体および方法並びに免疫チェックポイント阻害剤との併用における使用
KR20240038769A (ko) 항-ilt3 항체를 사용하여 급성 골수성 백혈병을 치료하는 방법
US11079381B2 (en) Risk-stratification of B-precursor acute lymphoblastic leukemia patients
HK40042585A (en) Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects
HK1190642B (en) Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects
HK1190642A (en) Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects